InsightsProcurement & Tenders

A pharma tender can clear every compliance check and still fail the patient.

By Uttam Dinodia2 min readView this post on LinkedIn

The people around the deal keep shifting. The rules meant to protect them rarely move at all.

The file is complete. The bid is evaluated. The award is issued. The supplier even ships.

And yet the patient who needs continuity, the hospital that needs workable pack sizes, the regulator that needs clean documentation, the donor that needs traceability: each one assumes someone else is representing them.

Usually, no one is.

That is the gap the Clarkson Principles of Stakeholder Management were built to close.

They are a governance standard for how organisations treat the groups affected by their decisions. Developed at the Clarkson Centre between 1993 and 1998, they were never a checklist. Clarkson called them meta-principles: rules for writing better rules.

For pharma procurement, they turn into seven questions worth asking before you sign anything:

1. Are we monitoring every legitimate stakeholder?
If you cannot name who represents a group, that group is not represented.

2. Are we communicating risk openly?
Not just price risk. Quality, shelf life, registration, cold chain, payment, delay. A risk hidden at tender stage becomes a crisis at delivery.

3. Does the process match capacity?
One process fits no one. A sterile injectable is not an oral solid. An overseas manufacturer carries a heavier documentation burden than a local distributor.

4. Are benefits and burdens shared fairly?
The lowest price is rarely the lowest system cost. Someone always pays for unrealistic lead times and unclear specs, usually the weakest link in the chain.

5. Are public and private actors cooperating early enough?
Clearance, import permits, donor timelines and last-mile distribution sit in different hands. The patient experiences them as one system.

6. Are we refusing the wrong trade?
Some trade-offs should be named before they are accepted. Margin against continuity. Speed against documentation. Not every saving is a saving.

7. Are we naming the conflict of interest?
An unnamed conflict becomes a design flaw. It resurfaces later as weak evaluation, selective communication or incentives that reward the wrong outcome.

Here is the real lesson.

The principles alone are not enough. Rechecking them each cycle is what turns stakeholder intent into structure rather than decoration.

A tender clause copied from last year does not fail merely because it is wrong. It fails because no one retested whether the stakeholder map still holds.

The people keep moving. Demand shifts, regulation changes, supplier capacity changes. The framework holds steady, but the document built on it stays frozen. That gap is where risk collects.

Compliance asks whether you followed the process.
Stakeholder management asks whether the process still protected the people carrying the risk.

Look at your biggest tender. Is the patient actually represented, yes or no?

Uttam Dinodia

Uttam Dinodia

Pharmaceutical Business Consultant & Executive Director, A One Afro Limited

Over 22 years in pharmaceutical supply. Helps international manufacturers and Zambian institutions with public tenders, ZAMRA regulatory pathways and distribution.